Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 801 results for "for merck"

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU

Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy Yahoo! Finance, 1 hour ago

Merck reports rise of USD0.01 per outstanding share in quarterly dividend

The board of directors of health care company Merck (NYSE:MRK) on Tuesday declared a higher quarterly dividend of USD0.46 per outstanding share of the company's common stock. This dividend marks an improvement of USD0.01 from the prior quarter ...
 Bloomberg2 days ago Merck & Co. Inc (MRK) Closes 0.45% Up on the Day for November 27  Equities.com9 minutes ago Will Merck (MRK) Stock Be Helped by Dividend Hike?  TheStreet.com3 days ago Merck & Co., Inc. Declares Quarterly Dividend of $0.46 (MRK)  American Banking News - Forex3 days ago

Merck KGaA Considers Sale Of Allergopharma To Reduce Debt: Bloomberg

German drug maker Merck KGaA (MKGAY.PK) is considering a sale of its allergy business, known as Allergopharma, as it seeks to reduce debt following the $17 billion takeover of Sigma-Aldrich Corp., the Bloomberg reported, citing people with knowledge ...
 RTTNews.com18 hours ago Merck to dispose of allergy unit: Bloomberg  M&A Portal10 hours ago MERCK KGAA : May Sell Allergopharma for up to USD638 Million  4 Traders16 hours ago Merck KGaA Said to Weigh Allergy Therapy Unit Sale to Trim Debt  FirstWord Pharma23 hours ago
MSN Philippines

Merck KGaA Said to Weigh Selling its Allergy Therapy Unit

Merck may fetch about 600 million euros from business sale Sale could attract strategic bidders and buyout firms Merck KGaA is considering a sale of its allergy business as the German company seeks to reduce debt following the $17 billion ...
 Bloomberg12 hours ago PE firms eyeing €600m bid for Merck's allergy business  AltAssets.net8 hours ago MERCK KGAA : plans to sell its allergy business unit to cut debt: Bloomberg  4 Traders23 hours ago Merck plans to sell its allergy business unit to cut debt  Financial Express15 hours ago

German stocks - Factors to watch on November 27

Nov 27 The following are some of the factors that may move German stocks on Friday: MERCK German drugs and chemicals maker Merck KGaA is planning to sell its allergy business, Allergopharma, Bloomberg reported, citing sources. SIEMENS The ...
 Reuters15 hours ago

Keytruda: Hope for Merck's Immuno-Oncology Franchise

Merck & Co.'s 3Q15 Earnings Show a Positive Future ( Continued from Prior Part ) Keytruda Keytruda is a prescription medicine. It's in Merck &Co.'s (MRK) immuno-oncology franchise. The drug treats non-small cell lung cancer as well as ...
 Yahoo! Finance1 day ago Remicade: A Falling Drug in Merck's Immunology Franchise  Yahoo! Finance1 day ago

MEDIA-Merck KGaA aims to put out a new drug every year -WirtschaftsWoche

FRANKFURT Nov 26 ** Merck KGaA aims to bring to market one new drug every year from 2017 onward, starting with cancer treatment avelumab, incoming CEO Stefan Oschmann tells German weekly business magazine WirtschaftsWoche ** Outgoing CEO ...
 Reuters UK1 day ago
IT News Africa

Merck tech will monitor HIV through Africa

Merck has hosted a discussion with researchers to discuss the intention to launch its innovative Muse Auto CD4/CD4% System, a portable instrument for monitoring the progression of the HIV/AIDS virus, throughout Africa. Regulatory approval has been ...
 IT-Online3 days ago Merck to launch HIV monitoring system for Africa  IT News Africa3 days ago

Merck declares $0.46 dividend

To screen ETFs by asset class, performance, yield and more, check out the ETF Hub.
 Seeking Alpha3 days ago
Motley Fool

Will Merck & Co. Be the One to Finally Take Down Gilead?

Life Sciences Jobs About a year ago, while we were still waiting for Viekira Pak from AbbVie to hit pharmacy shelves, many Gilead Sciences (NASDAQ:GILD) investors were worried the competitor would consume a hefty chunk of the overall hepatitis C ...
 BioSpace3 days ago Will Merck & Co. (MRK) Be the One to Finally Take Down Gilead (GILD)? 11/24/2015  ClinicSpace3 days ago Can Merck & Co. Take Down Gilead Sciences?  Motley Fool4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less